Arcadia Biosciences financials
$0.2807−8.86%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.1M | $901.0K | $1.3M | $1.5M | $1.2M | $1.2M | $1.5M | $1.3M | $987.0K | $777.0K | $1.3M |
| Gross profit | $631.0K | $400.0K | $192.0K | $418.0K | $631.0K | $518.0K | $389.0K | $505.0K | $673.0K | $516.0K | $599.0K | $480.0K |
| Gross margin | 43.7% | 36.4% | 21.3% | 32.1% | 43.4% | 43.2% | 32.0% | 32.9% | 51.5% | 52.3% | 77.1% | 37.0% |
| Operating income | -$496.0K | -$779.0K | -$1.4M | -$1.2M | -$6.0M | $530.0K | -$2.3M | -$1.8M | -$2.0M | -$1.6M | -$1.2M | -$1.4M |
| Net income | -$6.3M | -$4.4M | -$1.3M | $856.0K | -$4.5M | $2.6M | -$1.3M | -$1.6M | $1.1M | -$2.4M | -$2.9M | -$2.6M |
| Net margin | −434.2% | −398.6% | −148.3% | 65.7% | −306.4% | 216.6% | −110.4% | −104.9% | 81.2% | −245.5% | −367.2% | −197.8% |
| Diluted EPS | $-2.09 | $-2.11 | $-0.98 | $0.62 | $-3.26 | $1.90 | $-0.98 | $-1.18 | $0.78 | $-1.78 | $-2.09 | $-1.89 |
| EBITDA | -$496.0K | -$771.0K | -$1.4M | -$1.1M | -$6.0M | $543.0K | -$2.3M | -$1.8M | -$2.0M | -$1.5M | -$1.0M | -$1.3M |
| Operating cash flow | -$319.0K | -$1.1M | -$861.0K | -$257.0K | -$2.0M | -$1.6M | -$2.2M | -$1.8M | -$2.5M | -$3.2M | -$4.1M | -$2.9M |
| Free cash flow | -$319.0K | -$1.1M | -$861.0K | -$257.0K | -$2.0M | -$1.6M | -$2.2M | -$1.8M | -$2.5M | -$3.2M | -$4.1M | -$2.9M |
| Diluted shares | 3.0M | 2.1M | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.2M | $954.0K | $259.0K | $1.1M | $1.4M | $3.2M |
| Short-term investments | $0.00 | $2.8M | $4.3M | $4.8M | $3.1M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.9M | $5.3M | $6.5M | $8.6M | $7.8M | $13.0M |
| Total liabilities | $5.3M | $2.4M | $2.4M | $3.1M | $3.3M | $4.1M |
| Shareholders' equity | $633.0K | $2.9M | $4.1M | $5.4M | $4.5M | $8.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology